Blood Coagulation Disorders Clinical Trial
Official title:
A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months
Verified date | October 2018 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
With the advent of measures to try to decrease the incidence of transfusion-related acute
lung injury (TRALI), the Blood Bank industry is attempting to avoid collection of plasma from
female donors who have been pregnant in order to reduce the transfusion of plasma that may
contain HLA antibodies. This has led to a decrease in the number of donors available for the
production of fresh frozen plasma (FFP). Per Blood Bank regulatory standards in the United
States, FFP must be frozen within 8 hours of collection. Plasma that is frozen within 24
hours of collection is called FP24, and it is produced when whole blood cannot be processed
within the 8-hour time period for the generation of FFP. Studies of coagulation factors in
FFP and FP24 have shown that coagulation factor activities are adequate to maintain
hemostasis in both products. Many hospitals are using FFP and FP24 interchangeably in adults,
and occasional hospitals are using these products interchangeably in neonates. However,
studies concerning the use of FP24 in neonates have not been performed.
The investigators propose a single center prospective pilot study comparing the clinical
efficacy of FFP vs. FP24 in 50 nonsurgical neonates and babies up to age 6 months requiring
plasma for an International Normalization Ratio (INR) of 1.5 or more.
This protocol describes a pilot study to compare the use of FFP with FP24 in nonsurgical
neonates. Use of plasma in these cases is mostly for patients with perinatal hypoxia or
necrotizing enterocolitis and an INR of 1.5 or more. Transfusion of plasma (10 to 15 ml/kg)
is performed for these patients approximately every 8, 12, or 24 hours, as deemed indicated
by the patient's clinicians, and monitored with prothrombin time (PT), partial thromboplastin
time (PTT), and INR.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 6 Months |
Eligibility |
Inclusion Criteria: - Nonsurgical neonates and babies up to age 6 months with INR 1.5 or more who are deemed clinically to need plasma infusion. Exclusion Criteria: - Patients who are being prepared for surgery, or during or after surgery. - Patients with congenital anomalies, chromosomal anomalies, or heart defects. - Patients whose parents refuse to consent. |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of neonates with corrected International Normalization Ratio (INR)upon transfusion with plasma frozen within 24 hours of collection (FP24) | The investigators will compare fresh frozen plasma (FFP) with FP24 in correcting INR in 50 nonsurgical neonates | 24 hrs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Completed |
NCT01435304 -
The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
Completed |
NCT00091494 -
Socioeconomic Patterning of Inflammation and Hemostasis - Ancillary to MESA
|
N/A | |
Completed |
NCT00005481 -
Epidemiology of Impaired Coagulant Balance in Diabetes
|
N/A | |
Recruiting |
NCT02379104 -
ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals
|
N/A | |
Recruiting |
NCT01930916 -
Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients
|
N/A | |
Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
Completed |
NCT01787552 -
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02782338 -
The Effect of Voltaren-ophtha 0.1% Eye Drops on INR Levels (International Normalized Ratio) in Patients Taking Warfarin
|
N/A | |
Unknown status |
NCT01349712 -
Study to Test the Accuracy of a Prototype Handheld PT/INR Device
|
N/A | |
Completed |
NCT01143909 -
Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients
|
N/A | |
Recruiting |
NCT04762550 -
Thrombin Generation in Liver Transplant Surgery
|
||
Withdrawn |
NCT01221389 -
Study Using Plasma for Patients Requiring Emergency Surgery
|
Phase 4 | |
Withdrawn |
NCT00233246 -
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures
|
Phase 3 | |
Recruiting |
NCT03884725 -
Fibrinogen Concentrate In Children Cardiac Surgery 2
|
Phase 4 | |
Completed |
NCT00086476 -
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
|
N/A | |
Completed |
NCT00516126 -
Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery
|
Phase 4 | |
Completed |
NCT00708435 -
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
|
Phase 3 | |
Recruiting |
NCT00214656 -
"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
|
Phase 3 |